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Background: Microglia are resident macrophage-like cells in the central nervous system (CNS) and cause innate
immune responses via the LPS receptors, Toll-like receptor (TLR) 4 and CD14, in a variety of neuroinflammatory
disorders including bacterial infection, Alzheimer’s disease, and amyotrophic lateral sclerosis. Granulocyte
macrophage-colony stimulating factor (GM-CSF) activates microglia and induces inflammatory responses via
binding to GM-CSF receptor complex composed of two different subunit GM-CSF receptor α (GM-CSFRα) and
common β chain (βc). GM-CSF has been shown to be associated with neuroinflammatory responses in multiple
sclerosis and Alzheimer’s disease. However, the mechanisms how GM-CSF promotes neuroinflammation still
remain unclear.
Methods: Microglia were stimulated with 20 ng/ml GM-CSF and the levels of TLR4 and CD14 expression were
evaluated by RT-PCR and flowcytometry. LPS binding was analyzed by flowcytometry. GM-CSF receptor complex
was analyzed by immunocytechemistry. The levels of IL-1β, IL-6 and TNF-α in culture supernatant of
GM-CSF-stimulated microglia and NF-κB nuclear translocation were determined by ELISA. Production of nitric
oxide (NO) was measured by the Griess method. The levels of p-ERK1/2, ERK1/2, p-p38 and p38 were assessed by
Western blotting. Statistically significant differences between experimental groups were determined by one-way
ANOVA followed by Tukey test for multiple comparisons.
Results: GM-CSF receptor complex was expressed in microglia. GM-CSF enhanced TLR4 and CD14 expressions in
microglia and subsequent LPS-binding to the cell surface. In addition, GM-CSF priming increased LPS-induced NF-κB
nuclear translocation and production of IL-1β, IL-6, TNF-α and NO by microglia. GM-CSF upregulated the levels of
p-ERK1/2 and p-p38, suggesting that induction of TLR4 and CD14 expression by GM-CSF was mediated through
ERK1/2 and p38, respectively.
Conclusions: These results suggest that GM-CSF upregulates TLR4 and CD14 expression in microglia through
ERK1/2 and p38, respectively, and thus promotes the LPS receptor-mediated inflammation in the CNS.
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Microglia are resident macrophage-like cells in the
central nervous system (CNS). They become activated in
response to bacterial infection including gram-negative
bacteria, Candida albicans, and Cryptococcus neoformans,
and initiate an inflammatory response [1,2]. The principal
mechanism that initiates microglial response may be the
toll-like receptor (TLR) family of receptors [1,2]. TLRs
serve as pathogen-associated molecular pattern recogni-
tion receptors that bind microbial molecular motif with
high affinity, and play a central role in the initiation of
cellular innate immune responses [3]. TLR4 and CD14
are constitutively expressed in microglia [1,4] and their
ligand, lipopolysaccharide (LPS) induces production of
inflammatory mediators including TNF-α, IL-6, and
nitric oxide (NO) [4,5], via the nuclear factor κB (NF-κB)
signaling pathway [6].
It is reported that TLR4 on microglia recognizes fibrillar
Aβ [7]. Activation of TLR4 is reported to be associated
with increased production of TNF-α and IL-1β in the
CNS of APPswe/PS1 transgenic mice, a mouse model of
Alzheimer’s disease (AD) [8]. Genetic deficiency in CD14
reduces Aβ-induced microglial NO and IL-6 production
[9], and Alzheimer pathology in APPswe/PS1 transgenic
mice [10], suggesting that the LPS receptor plays an
important role in inflammation in AD. Furthermore, human
mutations in (Cu/Zn) superoxide dismutase-1 (mSOD1)
G93A and G85R, which cause non-cell-autonomous motor
neuron death in amyotrophic lateral sclerosis (ALS), activate
microglia and induce production of inflammatory media-
tors, including TNF-α, IL-1β, and NO [11]. TLR4 expres-
sion in microglia is reportedly increased in the spinal
cord of ALS patients [12]. Thus, these findings suggest
that the LPS receptor plays an important role, not only in
pathogen-induced inflammation, but also in inflammation
caused by misfolded protein, like fibrillar Aβ and mSOD1
in neurodegenerative diseases.
Granulocyte macrophage colony-stimulating factor
(GM-CSF) is a pleiotropic cytokine secreted by a wide
variety of cells including endothelial cells, monocytes, astro-
cytes, and T cells [13-17]. GM-CSF exerts its biological
function by binding to GM-CSF receptor complex com-
posed of two different subunits of GM-CSF receptor
alpha (GM-CSFRα) which shows ligand-specific bind-
ing, and a common β (βc) subunit, which is shared with
closely associated cytokines IL-3 and IL-5, and acts as
the signal transduction chain [18,19]. GM-CSF signal is
transmitted through Janus kinase (JAK) 2, mitogen acti-
vated protein kinase (MAPK) and phosphatidylinositol
3-kinase (PI3K) [20-22].
GM-CSF has been shown to be upregulated in various
neurological disorders like AD, vascular dementia, multiple
sclerosis (MS) [23,24]. Indeed, GM-CSF-deficient mice
are reportedly resistant to experimental autoimmuneencephalomyelitis, an animal model of MS [16,17], in
which microglial activation is reduced. Moreover,
neutralization of GM-CSF by antibodies suppresses
microglial activation in the cerebral cortices of the
mouse model of AD, Tg2576 mice [25]. Thus, it is
expected that GM-CSF is associated with promoting
CNS inflammation via microglial activation. We previously
reported that GM-CSF was able to induce phagocytosis,
proliferation, IL-6 production, and MHC class II expression
in microglia [26,27]. However, GM-CSF by itself failed to
induce some proinflammatory mediators such as TNF-α
and NO, suggesting that GM-CSF might promote
inflammation in the CNS via activating microglia
both directly and indirectly. However, the mechanisms by
which GM-CSF enhances such a broad neuroinflammatory
response are still far from clear.
Here, we show that the GM-CSF receptor complex,
GM-CSFRα and GM-CSFRβ, is strongly expressed in
microglia. GM-CSF enhances TLR4 and CD14 expression
in microglia, leading to increase of LPS-induced NF-κB
nuclear translocation and increased LPS-mediated IL-6,
TNF-α, and NO production. GM-CSF-induced expres-
sion of TLR4 and CD14 was mediated through ERK1/2
and p38, respectively. These results suggest that GM-CSF
promotes the LPS receptor-mediated neuroinflammation
via upregulating TLR4 and CD14 expression in microglia.
Material and methods
Reagents
Recombinant mouse GM-CSF was obtained from R&D
systems (Minneapolis, MN, USA). LPS was obtained
from Sigma-Aldrich (St Louis, MO, USA). Wortmannin
(PI3K inhibitor), U0126 (MEK1/2 inhibitor), SB203580
(p38 inhibitor), SP600125 (c-Jun N-terminal kinase (JNK)
inhibitor), and NF-κB inhibitor SN50 were obtained from
Calbiochem (Gibbstown, NJ, USA). Anti-phospho-p44/
42 MAPK (p-ERK1/2), anti-p42/44 MAPK antibodies
(extracellular signal-regulated kinase 1/2: ERK1/2), anti-
phospho-p38 and anti-p38 were obtained from Cell Sig-
naling Technology (Danvers, MA, USA). The other
antibodies used were as follows: anti-TLR4 (eBioscience,
San Diego, CA, USA), anti-CD14 (BioLegend, San Diego,
CA, USA), anti-CD11b (Serotec, Kidlington, UK), anti-
GFAP (Dako, Glostrup, Denmark), anti-Iba1 (Wako,
Osaka, Japan), anti-MAP2 (Merck Millipore, Billerica,
MA, USA), anti-GM-CSFRα (R&D systems, Minneapolis,
MN, USA), and anti-NeuN (Merck Millipore).
Cell culture
All animal experiments were conducted under proto-
cols that were approved by the Animal Experiment
Committee of Nagoya University. All primary cul-
tures were prepared from C57BL/6 mice (Japan SLC,
Hamamatsu, Japan).
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cell cultures prepared from newborn mice on day 14
using the shaking-off method as previously described
[27]. The purity of the cultures (> 99%) was deter-
mined by anti-CD11b immunostaining. The cultures
were maintained in Dulbecco’s modified Eagle’s mini-
mum essential medium (Sigma-Aldrich) supplemented
with 10% fetal bovine serum (SAFC Biosciences, Lenexa,
KS, USA), 5 μg/ml bovine insulin (Sigma-Aldrich), and
0.2% glucose.
Primary neuronal cultures were prepared from the
cortices of embryos at embryonic day 17 (E17) as
described previously [28]. Briefly, cortical fragments
were dissociated into single cells in dissociation solution
(Sumitomo Bakelite, Akita, Japan) and resuspended in
nerve culture medium (Sumitomo Bakelite). Neurons
were seeded onto 12-mm polyethyleneimine-(PEI)-coated
glass cover slips (Asahi Techno Glass Corp, Chiba, Japan)
at a density of 5 × 104 cells/well in 24-well plates. The
purity of the culture was more than 95% as determined
by NeuN-specific immunostaining.
Primary astrocytes were isolated as previously described
[29]. Briefly, microglial cells were removed from mixed
glial cell cultures from newborn mice and the remaining
cultures were trypsinized and re-plated in tissue culture
plates. Cultures after three passages were used as astro-
cytes. The purity of the culture was more than 95%
as determined by glial fibrillary acidic protein (GFAP)-
specific immunostaining.
Reverse transcription (RT)-PCR
For quantitative PCR, microglia were treated with GM-CSF
(20 ng/ml) for varying times (6 to 72 h). Similarly, microglia
were treated with GM-CSF (20 ng/ml) for 48 h or left
untreated in RepCellW (CellSeed, London, UK), in which
cells are adherent at 37°C but detach from the plate at 20
to 25°C. Then the cells were harvested, washed twice and
seeded on 24-well plates at a density of 1 × 105 cells/well.
After stimulation with varying concentrations of LPS for
48 h, the total cellular RNA was extracted using the
RNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA was
synthesized from total cellular RNA that was denatured
for 5 minutes at 65°C, followed by reverse transcription
reaction using the SuperScript II (Life Technologies,
Carlsbad, CA, USA). The cDNA served as a template to
amplify genes in RT-PCRs with TaqMan Gene Expression
assays (Applied Biosystems), Universal PCR Master Mix
(Applied Biosystems), and Rotor-Gene Q (Qiagen). Ex-
pression levels of target genes were calculated using a
comparative method and normalized to GAPDH expres-
sion levels as previously described [30]. The following
primers and probes were obtained from Applied Biosys-
tems: IL-1β, Mm00434228_m1; IL-6, Mm00446190_m1;
TNF-α, Mm00443258_m1; GAPDH, Mm99999915_g1;NOS2, Mm00440502_m1; CD14, Mm00438094_m1;
and TLR4, Mm00445273_m1.
For semi-quantitative PCR, the total cellular RNA from
astrocytes, neurons and microglia were extracted using the
RNeasy Mini Kit (Qiagen). cDNA was synthesized from total
cellular RNA as described above with SuperScript II (Life
Technologies) and semiquantitative PCR was performed using
Ampli Taq DNA polymerase (Applied Biosystems) as previ-
ously described [31] using the following the specific primer
sets: GAPDH GAPDH sense, 50–ACTCACGGGAAATTCA
ACG–30; GAPDH antisense, 50–CCCTGTTGCTGTAGCCG
TA–30; GM-CSFRα sense, 50–TGGCGAACGACTTGTCA
CTGCT–30; GM-CSFRα antisense, 50–GCACCTTGA
CCTTGTGACCT–30; GM-CSFRβ sense, 50–TGTTCCA
GGATGGAGGTAAA–30; GM-CSFRβ an-tisense, 50–C
CCACACTGCACATCCATAG–30.
Flow cytometry (FCM)
FCM was done as previously described [26]. Briefly, micro-
glia cells treated with GM-CSF or left untreated were
blocked with Fc block for 30 minutes in fluorescence-
activated cell sorter (FACS) buffer and then cells were
stained with phycoerythrin (PE)-conjugated-anti-TLR4, PE-
conjugated-anti-CD14, or isotype-matched control. The
cells were subsequently analyzed using a Cytomics FC500
(Beckman Coulter, Brea, CA, USA). To assess LPS binding,
microglia cultured in the presence or absence of GM-CSF
for 48 h, were treated with Alexa 488-conjugated LPS for
1 h. After washing twice to remove any unbound LPS, cells
were analyzed using a Cytomics FC500.
Immunocytochemistry
Immunocytochemistry was done as previously described
[32]. Microglia, astrocytes or neurons plated on glass
cover slips were fixed with 4% paraformaldehyde for
10 minutes, cells were then permeabilized with 0.05%
Triton X-100 for 5 minutes and blocked with 5% goat
serum for 1 h, followed by incubation with anti-iba1,
anti-GFAP, or anti-MAP2 and GM-CSFRα, antibodies
overnight at 4°C. Then, the cells were incubated with
Alexa 488- or Alexa 568-conjugated secondary anti-
bodies for 1 h. Cells were examined with a deconvolu-
tion fluorescence microscope system (Bio Zero, Keyence,
Osaka, Japan).
Measurement of NO and cytokines
Microglia were treated with GM-CSF for 48 h or left
untreated in RepCell. Then the cells were harvested,
washed twice and seeded at a density of 1 × 105 cells/
well in 24 well plates. Then the cells were treated with
varying concentrations of LPS (0.01 to 1 μg/ml) for 48 h.
Supernatants were collected and NO production was deter-
mined by the Griess reaction as previously described [31].
The levels of IL-1βIL-6 and TNF-α in culture supernatant
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turer’s instructions (BD Biosciences).
NF-κB nuclear translocation
Microglia primed with GM-CSF for 48 h or left untreated
were seeded on 6-well plates at 1 × 107 cells/well and trea-
ted with LPS (1 μg/ml) for 0 to 30 minutes. Nuclear frac-
tions from the cells were separated and the levels of NF-κB
in the nuclear fractions were analyzed using the NF-κB/
p65-active ELISA kit (Imgenex, San Diego, CA, USA)
according to the manufacturer’s instructions.
Western blotting
Microglia were treated with GM-CSF (20 ng/ml) for
varying times (15 to 120 minutes). After washing withB
A
Figure 1 Granulocyte macrophage-colony stimulating factor (GM-CSF
the central nervous system (CNS). (A) The expression levels of GM-CSF R
analyzed by semi-quantitative PCR. (B) Surface expression of GM-CSF Rα in
immunocytochemistry. Data are representative of three independent experPBS, cells were lysed with TNES buffer (1 M Tris–HCl,
20% SDS and 2.5% glycerol) containing phosphatase
(Sigma-Aldrich) and protease inhibitor (Roche, Mannheim,
Germany); 50 μg of protein from the total lysate was
assayed for phosphorylated ERK1/2, phosphorylated p38,
total ERK and total p38 by western blotting as described
previously [31].Statistical analysis
Statistically significant differences between experimental
groups were determined by one-way analysis of variance
(ANOVA) followed by Tukey test for multiple comparisons.
Statistical analysis was performed using the software
program Prism 4.0 (GraphPad Software, San Diego,) receptor complex is predominantly expressed in microglia in
α and GM-CSF Rβ mRNA in neurons, astrocytes, and microglia were
neurons, astrocytes and microglia was analyzed by
iments. Scale bar represents 50 μm.
AB
C
Figure 2 Granulocyte macrophage-colony stimulating factor (GM-CSF) increases toll-like receptor (TLR) 4 and CD14 expression in
microglia. (A) Microglia were treated with GM-CSF (20 ng/ml) for 6 to 72 h and analyzed for expression of TLR4 and CD14 mRNA by real-time
PCR. (B, C) Microglia treated with GM-CSF at 20 ng/ml were analyzed for surface expression of TLR4 and CD14 by flow cytometry (FCM). Data
indicate mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 (GM-CSF-treated vs. -untreated).
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statistically significant.Results
GM-CSFR complex is expressed in microglia
We first assessed the basal expression of GM-CSFRα and
GM-CSFRβ mRNA in microglia, astrocytes and neurons.
Microglia expressed both GM-CSFRα and GM-CSFRβ
mRNA (Figure 1A). The expression of GM-CSFRα and
GM-CSFRβ mRNA in astrocytes and GM-CSFRβ mRNA
in neurons was very weak (Figure 1A). Immunocyto-
chemistry confirmed that microglia, but not neurons
and atrocytes, expressed GM-CSFRα protein (Figure 1B).
These results indicate that functional GM-CSFR is
expressed in microglia in the CNS.Figure 3 Granulocyte macrophage-colony stimulating factor
(GM-CSF) enhances lipopolyssacharide (LPS) binding to
microglia. Microglia were treated with GM-CSF at 20 ng/ml for 48 h
and then treated with Alexa 488-conjugated LPS for 1 h. Cells were
examined by flow cytometry (FCM). Data indicate mean ± SD of
three independent experiments.GM-CSF increases TLR4 and CD14 expression in microglia
We next assessed expression of the LPS receptor, TLR4,
and CD14 in microglia. GM-CSF time-dependently
increased expression of TLR4 and CD14 mRNA, which
peaked at 48 h and remained stabilized until 72 h in
microglia (Figure 2A). FCM also showed that GM-CSFupregulated the surface expression of TLR4 and CD14
in microglia, which peaked at 48 h and remained stabi-
lized until 72 h (Figure 2B and C). To further confirm
that GM-CSF increased the LPS receptor expression, we
assessed binding of Alexa488-conjugated LPS in GM-
0 0.01 0.1 1
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Figure 4 (See legend on next page).
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Figure 4 Granulocyte macrophage-colony stimulating factor (GM-CSF) increases lipopolysaccharide (LPS)-induced IL-6, nitric oxide
(NO), and TNF-α production. After pretreating with GM-CSF or leaving untreated for 48 h, microglia were harvested, washed twice, and seeded
at 1 × 105 cells/well. Then the cells were treated with varying doses of LPS (0.01 to 1 μg/ml) for 48 h. (A) The expression levels of IL-1β, IL-6, TNF-
α and NOS2, mRNA were assessed by quantitative real-time PCR. (B) Concentrations of IL-1β, IL-6, TNF-α , and NO in culture supernatant were
analyzed by ELISA and the Griess method. Data indicate mean ± SD. Data are representative of three independent experiments. ***P < 0.001
(GM-CSF pretreated vs. untreated).
0 15 30 (min)
Figure 5 Granulocyte macrophage-colony stimulating factor
(GM-CSF) enhances lipolysaccharide (LPS)-induced nuclear factor
(NF)-κB nuclear translocation. After pretreating with GM-CSF or
leaving untreated for 48 h, microglia were harvested, washed twice,
and seeded at a density of 1 × 107 cells/well. Then the cells were
treated with LPS (1 μg/ml) for varying times (0 to 30 minutes).
Nuclear fractions from the cells were separated and the levels of
NF-kB/p65 in the nuclear fractions were assessed by ELISA. Data
are representative of three independent experiments. ***P < 0.001
(GM-CSF-pretreated vs. -untreated).
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increased the surface binding of LPS (Figure 3). These
results indicate that GM-CSF increase expression of TLR4
and CD14 in microglia.
GM-CSF enhances LPS-induced production of
inflammatory mediators
We then examined whether GM-CSF affects LPS-mediated
function in microglia. We pretreated microglia with
GM-CSF for 48 h, then the cells were harvested, washed,
seeded at a density of 1 × 105 cells/well in 24-well plates,
and further stimulated with varying doses of LPS (0.01 to
1 μg/ml) for 48 h. GM-CSF priming increased LPS-induced
expression of IL-1β, IL-6, TNF-α and NOS2 mRNA as
compared to unprimed microglia (Figure 4A). Similarly,
GM-CSF priming increased LPS-induced secretion of
IL-1β, IL-6, TNF-α and NO (Figure 4B).
NF-κB plays a critical role in the production of various
proinflammatory molecules, including IL-6 and TNF-α, by
activation of TLR4 [6]. To further characterize GM-CSF
priming of LPS response, to find out whether increased
TLR4 and CD14 are associated with enhanced nuclear
translocation of NF-kB, we assessed nuclear translocation of
NF-kB. GM-CSF priming significantly increased the levels
of LPS-induced NF-κB nuclear translocation as compared
to unprimed cells (Figure 5). To reveal the requirement of
NF-κB in LPS-induced increased production of cytokines in
GM-CSF-primed or -unprimed cells, we inhibited NF-κB
signaling with SN50 before LPS stimulation, and assessed
IL-1β, IL-6, TNF-α and NO production by ELISA and
Griess reagent, respectively. SN50 dose-dependently inhib-
ited production of LPS-induced IL-1β, IL-6, TNF-α and NO
in both unprimed and GM-CSF-primed microglia, although
a higher dose was required to completely inhibit the pro-
duction of IL-1β, IL-6, TNF-α, and NO in GM-CSF-primed
microglia (Figure 6). These results indicate that GM-CSF
priming increases LPS-mediated production of IL-1β, IL-6,
TNF-α and NO via increasing activation of NF-κB.
GM-CSF-induced expression of TLR4 and CD14 is
mediated via ERK1/2 and p38 activation, respectively
GM-CSF has been shown to activate JAK2, PI3K, ERK1/2,
and p38 in microglia [20-22]. We evaluated the pathway
involved in GM-CSF-induced upregulation of TLR4 and
CD14 expression in microglia. JAK2 inhibitor, PI3Kinhibitor, Wortmannin, and NF-κB inhibitor, SN50 had no
effect in GM-CSF-induced increase of TLR4 and CD14 ex-
pression. The MEK1/2 inhibitor, U0126 (1 μM/ml) sup-
pressed GM-CSF-induced surface expression of TLR4 but
did not reach basal level (Figure 7A). SB203580 had no ef-
fect in the surface expression TLR4. In contrast, the p38 in-
hibitor, SB203580 (1 μM/ml) suppressed GM-CSF-induced
surface expression of CD14 to basal level (Figure 7B).
U0126 had no effect in the surface expression of CD14. We
further assessed the phosphorylation of ERK1/2 and p38 by
western blotting. GM-CSF increased the levels of phos-
phorylated ERK1/2 and p38, respectively, which peaked at
15 minutes (Figure 7C). Accordingly, U0126, SB203580, or
U0126 + SB203580 pretreatment before GM-CSF priming
decreased LPS-mediated production of IL-1β, IL-6, TNF-α
and NO in microglia (Figure 8). Taken together, these data
indicate that GM-CSF increases TLR4 surface expression
via ERK1/2 and that of CD14 via p38.
Discussion
Here we have shown that GM-CSFR complex is expressed
















Figure 6 SN50 decreases lipolysaccharide (LPS)-induced production of IL-6, nitric oxide (NO), TNF-α both in granulocyte macrophage-
colony stimulating factor (GM-CSF)-treated and -untreated microglia. After pretreating with GM-CSF or leaving untreated for 48 h, microglia
were harvested, washed twice, and seeded at 1 × 105 cells/well. Then the cells were treated SN50 for 1 h before stimulation with LPS at 1 μg/ml
for 48 h. Concentrations of IL-1β, IL-6, TNF-α and NO were determined by ELISA and the Griess method. Data indicate mean ± SD. Data are
representative of three independent experiments. ***P < 0.001 (untreated and SN50-treated).
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required for binding GM-CSF, was found in GFAP-
positive astrocytes or in MAP2-positive cortical neurons.
In contrast to our finding, previous reports suggested ex-
pression of GM-CSFRα in astrocytes and neurons [33-35].
However, we could not find any staining in neurons and
astrocytes. However, we cannot rule out the possibility of
regional- or maturation-specific expression of GM-CSFRα
in neurons, as described previously, and upregulation of
GM-CSFRα in activated astrocytes under host-specific
conditions.
We showed that GM-CSF increased both mRNA and
surface expression of TLR4 and CD14 via activation of
ERK1/2 and p38, respectively, and pretreatment with
U0126, SB203580, or both, indeed inhibit LPS-induced
production of proinflammatory mediators in the micro-
glia incubated with GM-CSF. In the peripheral immune
system, it has been shown that peritoneal macrophages
from GM-CSF knockout mice are hyposensitive to LPS[36], and GM-CSF is required for the expression of
TLR4 and CD14 in alveolar macrophages [37]. Similarly,
we showed that GM-CSF enhances LPS-induced produc-
tion of inflammatory mediators by promoting TLR4 expres-
sion, which is consistent with a previous report showing
that the magnitude of LPS response correlates with total
TLR4 expression levels [38]. Moreover, Helicobacter pylori
LPS upregulate TLR4 expression via ERK1/2 in the gastric
epithelial cell line, MKN28, and GM-CSF reportedly
upregulate TLR4 expression via ERK1/2 in human blood
monocytes respectively [39,40]. GM-CSF is reported to be
required for CD14 expression in murine alveolar macro-
phages and human myeloid leukemia cells, whereas in
human blood monocytes GM-CSF has been found to
have no effect in CD14 expression [37,40,41]. Similarly, in
the human monocytic cell line U937, both p38 and
ERK1/2 activation have been shown to increase CD14 ex-
pression [42]. However, in our experiment, inhibiting p38
but not ERK1/2 decreased the surface expression of
+ GM-CSF (20 ng/ml)
Figure 7 Granulocyte macrophage-colony stimulating factor (GM-CSF) upregulates toll-like receptor (TLR) 4 and CD14 expression via
extracellular signal-regulated kinase (ERK) 1/2 and p38, respectively. (A, B) Microglia were pretreated with U0126 or SB 203580 for 1 h
before stimulation with 20 ng/ml GM-CSF for 48 h. Surface expression levels of TLR4 were assessed by flow cytometry (FCM) (A). Data indicate
mean ± SD of three independent experiments; P < 0.001 (between GM-CSF and GM-CSF + U0126), P < 0.05 (between NT and GM-CSF + U0126).
Surface expression levels of CD14 were assessed by FCM (B). Data indicate mean ± SD of three independent experiments; P < 0.001 (between
GM-CSF and GM-CSF + SB 203580); P > 0.05 (between NT and GM-CSF + SB 203580). (C) Microglia were treated with 20 ng/ml GM-CSF. Then cells
were lysed and total cell lysates were analyzed by western blotting for p-ERK1/2, ERK1/2, p-p38, and p38. Data are representative of two
independent experiments.
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tissue-resident monocyte/macrophage cell-like microglia,
alveolar macrophage and circulating monocytes.
TLR4 is required for the initiation of innate immune
responses to LPS [5,6]. CD14 is a key LPS co-receptor,
pivotal in the initial binding of LPS and transfer of LPS to
MD2/TLR4 complex to initiate signal cascades [43-46]. In
addition to LPS, various endogenous molecules such as
HMGB1 and HSP60, which are released from dying
cells, and misfolded proteins like mutant SOD1 and
fibriller Aβ, as well as fibronection, have been shown to
bind to TLR4 and CD14 [7,11,47-50]. Surface expression
of TLR4 and CD14 in microglia has been shown to be
elevated in various neurological disorders like ALS and
AD [12,51]. Indeed, chronic activation of TLR4 and
CD14 by LPS has been shown to exacerbate disease in
the mouse model of ALS [52]. It has also been shown thatextracellular mSOD1 interacts with CD14 in microglia,
which then associates with TLR2 and TLR4 activating the
proinflammatory cascade [11]. Similarly, Aβ has been
shown to bind both TLR4 and CD14 and induce
inflammation [7-10]. Thus, GM-CSF may function
to exacerbate ALS and AD by increasing TLR4 and
CD14 expression in microglia. Supporting this hypothesis,
GM-CSF knockout mice have been reported to have
delayed onset and increased life span in the mouse model
of ALS [53]. In addition, blocking GM-CSF with anti-GM-
CSF antibodies reportedly decreased microglial activation
in the mouse model of AD [25,54]. However, there are
several conflicting reports. GM-CSF is reported to be
beneficial in the mouse model of Parkinson’s disease and
in stroke [55,56]. Thus, it is possible that GM-CSF may
have both beneficial and detrimental effects, depending on
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Figure 8 Inhibition of extracellular signal-regulated kinase (ERK)
1/2, p38 decreases lipopolysaccharide (LPS)-induced production of
IL-1β, IL-6, TNF-α and nitric oxide (NO) in granulocyte macrophage-
colony stimulating factor (GM-CSF)-treated microglia. Microglia were
pretreated with U0126, SB 203580, or both, for 1 h and stimulated with
GM-CSF (20 ng/ml) or left untreated for 48 h. Then the cells were
harvested, washed twice, and seeded at a density of 1 × 105 cells/well in
24-well plates. Cells were further stimulated with LPS (1 μg/ml) for 48 h.
Concentrations of IL-1β, IL-6, TNF-α and NO were determined by ELISA
and the Griess method respectively. Data indicate mean ± SD. Data are
representative of two independent experiments. ***P< 0.001 (between
GM-CSF-primed and -unprimed), †††P< 0.001 (between GM-CSF-primed
and SB 203580-pretreated), ‡‡‡ P< 0.001 (between GM-CSF-primed and
U0126-pretreated), §§§ P< 0.001 (between GM-CSF-primed and SB
203580 +U0126-pretreated).
Parajuli et al. Journal of Neuroinflammation 2012, 9:268 Page 10 of 12
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logical disorders.
Conclusions
GM-CSF increases surface expression of TLR4 and
CD14 in microglia, which is mediated by ERK1/2 and
p38, respectively. Accordingly, GM-CSF upregulates
LPS-induced IL-1β, IL-6, TNF-α, and NO production
and may promote neuroinflammation.
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